A Double-Blind, Randomized, Placebo Controlled Study of CM_AT for the Treatment of Autism in Children 3-8 Years Old. (The Blüm Study)
Autism is clearly a significant cause of disability in the pediatric population. Many children with Autism exhibit impaired protein digestion which may or may not manifest in self-restricted diets. The inability to digest protein affects the availability of essential amino acids in the body. CM-AT is designed to enhance protein digestion thereby potentially restoring the pool of essential amino acids. Essential amino acids play a critical role in the expression of several genes important to neurological function and serve as precursors to key neurotransmitters such as serotonin and dopamine.
CM-AT is a proprietary enzyme that is designed as a granulated powder to be taken three times daily.
Watch this video to learn more about the Blüm Study, the clinical trial of CM-AT, an investigational new drug, for the treatment of Autism in children 3-8 years of age.
| Condition | Autism |
|---|---|
| Clinical Study Identifier | TX142059 |
| Last Modified on | 7 November 2020 |
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer
Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!
No annotations made yet
Congrats! You have your own personal workspace now.